Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective
Authors
Keywords
-
Journal
Nutrients
Volume 13, Issue 2, Pages 351
Publisher
MDPI AG
Online
2021-01-25
DOI
10.3390/nu13020351
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions
- (2020) Marieke Sternkopf et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials
- (2020) A. Mantovani et al. DIABETES & METABOLISM
- No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes
- (2020) Natasha C. Bergmann et al. DIABETES CARE
- Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
- (2020) Mansoor Husain et al. DIABETES OBESITY & METABOLISM
- Glucose-dependent insulinotropic peptide and risk of cardiovascular events and mortality: a prospective study
- (2020) Amra Jujić et al. DIABETOLOGIA
- Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes
- (2020) Mark L. Hartman et al. DIABETES CARE
- GIP as a therapeutic target in diabetes and obesity: insight from incretin co-agonists
- (2020) Jens Juul Holst et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A novel thrombin-based triagonist with diabetes-protective and weight-lowering potential
- (2020) Jingyu Zhang et al. LIFE SCIENCES
- Type 2 Diabetes Mellitus: A Review of Multi-Target Drugs
- (2020) Angelica Artasensi et al. MOLECULES
- Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
- (2020) Mengying Yang et al. Frontiers in Pharmacology
- A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
- (2020) John A. Dougherty et al. ANNALS OF PHARMACOTHERAPY
- Obesity in adults: a clinical practice guideline
- (2020) Sean Wharton et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Cardiovascular Outcomes Trials with Glucagon‐like Peptide‐1 Receptor Agonists: A Comparison of Study Designs, Populations, and Results
- (2020) Kevin M. Pantalone et al. DIABETES OBESITY & METABOLISM
- Effects and Safety of Sitagliptin in Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
- (2020) Yuhan Zhang et al. HORMONE AND METABOLIC RESEARCH
- Use of incretin-based medications: what do current international recommendations suggest with respect to GLP-1 receptor agonists and DPP-4 inhibitors?
- (2020) Melanie J. Davies et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- GLP-1 Analogues as a Complementary Therapy in Patients after Metabolic Surgery: a Systematic Review and Qualitative Synthesis
- (2020) Romano Schneider et al. OBESITY SURGERY
- The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes
- (2020) Jonathan M. Wilson et al. DIABETES OBESITY & METABOLISM
- Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map
- (2020) Jai Kumar et al. DIGESTIVE AND LIVER DISEASE
- Pathophysiology of Type 2 Diabetes Mellitus
- (2020) Unai Galicia-Garcia et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cardiovascular outcome trials in obesity: A review
- (2020) John P.H. Wilding et al. Obesity Reviews
- GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date
- (2020) Stephen A. Brunton et al. POSTGRADUATE MEDICINE
- Nutrient consumption-dependent association of a glucagon-like peptide-1 receptor gene polymorphism with insulin secretion
- (2020) Yuki Nishiya et al. Scientific Reports
- Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease
- (2020) Laurie L. Baggio et al. Molecular Metabolism
- Glucose-Dependent Insulinotropic Peptide in the High-Normal Range Is Associated With Increased Carotid Intima-Media Thickness
- (2020) Amra Jujić et al. DIABETES CARE
- New prospects for incretin‐related drugs in the treatment of type 2 diabetes
- (2020) Tomohiko Kimura et al. Journal of Diabetes Investigation
- The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials
- (2020) Thinzar Min et al. Diabetes Therapy
- Efficacy and Cardiovascular Safety of DPP-4 Inhibitors
- (2020) Nikhila A. Subrahmanyan et al. Current Drug Safety
- Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus
- (2019) Giorgio Sesti et al. ACTA DIABETOLOGICA
- Effects of lixisenatide on postprandial blood pressure, gastric emptying and glycemia in health and type 2 diabetes
- (2019) Karen L. Jones et al. DIABETES OBESITY & METABOLISM
- Identification of 28 new susceptibility loci for type 2 diabetes in the Japanese population
- (2019) Ken Suzuki et al. NATURE GENETICS
- Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study
- (2019) Natasha C. Bergmann et al. DIABETOLOGIA
- Evaluation of a rare glucose-dependent insulinotropic polypeptide receptor variant in a patient with diabetes
- (2019) Simon F. Jacobi et al. DIABETES OBESITY & METABOLISM
- Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failure
- (2019) Binayak Sinha et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- A double-blind, placebo-controlled, randomised trial to assess the effect of liraglutide on ectopic fat accumulation in South Asian type 2 diabetes patients
- (2019) Huub J. van Eyk et al. Cardiovascular Diabetology
- Body weight management and safety with efpeglenatide in adults without diabetes: a phase II randomized study
- (2019) Richard E. Pratley et al. DIABETES OBESITY & METABOLISM
- Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Consensus Recommendations on GLP-1 RA Use in the Management of Type 2 Diabetes Mellitus: South Asian Task Force
- (2019) Sanjay Kalra et al. Diabetes Therapy
- Clinical Use of DPP-4 Inhibitors
- (2019) Baptist Gallwitz Frontiers in Endocrinology
- Mechanism of Glucagon-Like Peptide 1 Improvements in Type 2 Diabetes Mellitus and Obesity
- (2019) Eric Nolen-Doerr et al. Current Obesity Reports
- Incretins in obesity and diabetes
- (2019) Chee W. Chia et al. Annals of the New York Academy of Sciences
- Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake
- (2019) Alice E. Adriaenssens et al. Cell Metabolism
- GLP-1: Molecular mechanisms and outcomes of a complex signaling system
- (2019) Nicholas K. Smith et al. NEUROCHEMISTRY INTERNATIONAL
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease
- (2019) Sebastian M. Heimbürger et al. PEPTIDES
- GIP analogues and the treatment of obesity-diabetes
- (2019) Clifford J. Bailey PEPTIDES
- The influence of Glucose-dependent Insulinotropic Polypeptide (GIP) on human adipose tissue and fat metabolism: Implications for obesity, type 2 diabetes and Non-Alcoholic Fatty Liver Disease (NAFLD)
- (2019) Sravan K. Thondam et al. PEPTIDES
- Physiological roles of the GIP receptor in murine brown adipose tissue
- (2019) Jacqueline L. Beaudry et al. Molecular Metabolism
- 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
- (2019) John B. Buse et al. DIABETOLOGIA
- Cardiovascular biology of the GIP receptor
- (2019) Amanda A. Greenwell et al. PEPTIDES
- Molecular interactions of full-length and truncated GIP peptides with the GIP receptor – A comprehensive review
- (2019) Maria Buur Nordskov Gabe et al. PEPTIDES
- Liraglutide Improves Non-Alcoholic Fatty Liver Disease In Diabetic Mice By Modulating Inflammatory Signaling Pathways
- (2019) Ying Luo et al. Drug Design Development and Therapy
- Glucagon-like peptide-1 receptor and sarcoglycan delta genetic variants can affect cardiovascular risk in chronic kidney disease patients under hemodialysis
- (2019) Annalisa Terranegra et al. Clinical Kidney Journal
- Glucagon-like peptide-1 regulates brown adipose tissue thermogenesis via the gut-brain axis in rats
- (2018) Jean-Philippe Krieger et al. AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY
- GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms
- (2018) Manfredi Rizzo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
- Semaglutide: Review and Place in Therapy for Adults with Type 2 Diabetes
- (2018) Ronald M. Goldenberg et al. Canadian Journal of Diabetes
- GLP-1 Receptor Agonists and Cardiovascular Disease: a Meta-Analysis of Recent Cardiac Outcome Trials
- (2018) Xiaoming Jia et al. CARDIOVASCULAR DRUGS AND THERAPY
- Nonsynonymous Variants inPAX4andGLP1Rare Associated with Type 2 Diabetes in an East Asian Population
- (2018) Soo Heon Kwak et al. DIABETES
- Endogenous GLP-1 alters postprandial functional connectivity between homeostatic and reward-related brain regions involved in regulation of appetite in healthy lean males: A pilotstudy
- (2018) Anne Christin Meyer-Gerspach et al. DIABETES OBESITY & METABOLISM
- Incretin hormones: Their role in health and disease
- (2018) Michael A. Nauck et al. DIABETES OBESITY & METABOLISM
- The effect of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists on energy expenditure: A systematic review and meta-analysis
- (2018) Michel Garcia Maciel et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Incretin-based therapy in type 2 diabetes: An evidence based systematic review and meta-analysis
- (2018) Greer Waldrop et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
- (2018) Philip Ambery et al. LANCET
- Allelic variant in the glucagon-like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study
- (2018) V. Chedid et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Newer GLP-1 receptor agonists and obesity-diabetes
- (2018) Emily Brown et al. PEPTIDES
- Novel role of GLP-1 receptor signaling in energy expenditure during chronic high fat diet feeding in rats
- (2018) Jean-Philippe Krieger et al. PHYSIOLOGY & BEHAVIOR
- Incretin responses to oral glucose and mixed meal tests and changes in fasting glucose levels during 7 years of follow-up: The Hoorn Meal Study
- (2018) A. D. M. Koopman et al. PLoS One
- Loss of dorsomedial hypothalamic GLP-1 signaling reduces BAT thermogenesis and increases adiposity
- (2018) Shin J. Lee et al. Molecular Metabolism
- The Origin and Understanding of the Incretin Concept
- (2018) Jens F. Rehfeld Frontiers in Endocrinology
- Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
- (2018) Simona Leoni et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Polymorphisms in the Glucagon-Like Peptide 1 Receptor (GLP-1R) Gene Are Associated with the Risk of Coronary Artery Disease in Chinese Han Patients with Type 2 Diabetes Mellitus: A Case-Control Study
- (2018) Xiaowei Ma et al. Journal of Diabetes Research
- Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine
- (2018) Gaia Chiara Mannino et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- GLP-1 receptor agonists and cardiovascular outcome trials: An update
- (2018) Eirini Andrikou et al. Hellenic Journal of Cardiology
- Modulation of Insulin Resistance in NAFLD
- (2018) Reenam Khan et al. HEPATOLOGY
- Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
- (2018) Juan Pablo Frias et al. LANCET
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics
- (2018) Stergios A. Polyzos et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Pharmacotherapy of obesity: Available medications and drugs under investigation
- (2018) Eleni Pilitsi et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
- (2018) Tamer Coskun et al. Molecular Metabolism
- Association of incretin receptors genetic polymorphisms with type 2 diabetes mellitus in Egyptian patients
- (2017) Sally M. Shalaby et al. JOURNAL OF GENE MEDICINE
- Protein-altering variants associated with body mass index implicate pathways that control energy intake and expenditure in obesity
- (2017) Valérie Turcot et al. NATURE GENETICS
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
- (2017) Matthew H. Secrest et al. TRENDS IN CARDIOVASCULAR MEDICINE
- Novel Common Variants Associated with Obesity and Type 2 Diabetes Detected Using a cFDR Method
- (2017) Qiang Zhang et al. Scientific Reports
- The effect of glucose-dependent insulinotropic polypeptide (GIP) variants on visceral fat accumulation in Han Chinese populations
- (2017) T Wang et al. Nutrition & Diabetes
- Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?
- (2017) Matthias Ploug Larsen et al. Journal of Diabetes Research
- Elevated hepatic DPP4 activity promotes insulin resistance and non-alcoholic fatty liver disease
- (2017) Christian Baumeier et al. Molecular Metabolism
- Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice
- (2017) Sigrid Jall et al. Molecular Metabolism
- Evaluation of Weight Loss and Adipocytokine Levels after Two Hypocaloric Diets with Different Macronutrient Distribution in Obese Subjects with the rs6923761 Gene Variant of Glucagon-Like Peptide 1 Receptor
- (2017) Daniel Antonio de Luis et al. ANNALS OF NUTRITION AND METABOLISM
- The Cardiovascular Biology of Glucagon-like Peptide-1
- (2016) Daniel J. Drucker Cell Metabolism
- Glucagon-Like Peptide 1 Receptor Activation Attenuates Platelet Aggregation and Thrombosis
- (2016) Alison Cameron-Vendrig et al. DIABETES
- Diabetes and obesity treatment based on dual incretin receptor activation: ‘twincretins’
- (2016) M. A. Skow et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
- (2016) J. Ard et al. DIABETES OBESITY & METABOLISM
- GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial
- (2016) Olivia M. Farr et al. DIABETOLOGIA
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) et al. DIABETOLOGIA
- Pathophysiology of Non Alcoholic Fatty Liver Disease
- (2016) Salvatore Petta et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Obesity: An overview of possible role(s) of gut hormones, lipid sensing and gut microbiota
- (2016) Alok Kumar Mishra et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The incretin system ABCs in obesity and diabetes - novel therapeutic strategies for weight loss and beyond
- (2016) A. L. João et al. Obesity Reviews
- A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease
- (2016) Robert A. Scott et al. Science Translational Medicine
- The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study
- (2016) Hudson Reddon et al. Scientific Reports
- Postprandial glucagon-like peptide-1 secretion is increased during the progression of glucose intolerance and obesity in high-fat/high-sucrose diet-fed rats
- (2015) Shingo Nakajima et al. BRITISH JOURNAL OF NUTRITION
- The glucagon-like peptide-1 (GLP-1) receptor agonist, exenatide, inhibits small intestinal motility, flow, transit and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomised controlled trial.
- (2015) Sony S. Thazhath et al. DIABETES
- Exenatide Regulates Cerebral Glucose Metabolism in Brain Areas Associated With Glucose Homeostasis and Reward System
- (2015) Giuseppe Daniele et al. DIABETES
- Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes
- (2015) Jennifer S. ten Kulve et al. DIABETES CARE
- Brain reward-system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans
- (2015) L. van Bloemendaal et al. DIABETES OBESITY & METABOLISM
- Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice
- (2015) Kristy M. Heppner et al. DIABETOLOGIA
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study
- (2015) Mojca Jensterle et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Genetic studies of body mass index yield new insights for obesity biology
- (2015) Adam E. Locke et al. NATURE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation
- (2015) Liselotte van Bloemendaal et al. Obesity
- European Guidelines for Obesity Management in Adults
- (2015) Volkan Yumuk et al. Obesity Facts
- Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease
- (2015) Darleen A. Sandoval et al. PHYSIOLOGICAL REVIEWS
- Replication Study in a Japanese Population to Evaluate the Association between 10 SNP Loci, Identified in European Genome-Wide Association Studies, and Type 2 Diabetes
- (2015) Ren Matsuba et al. PLoS One
- Low-frequency and rare exome chip variants associate with fasting glucose and type 2 diabetes susceptibility
- (2015) Jennifer Wessel et al. Nature Communications
- Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes
- (2015) Chia-Hung Lin et al. Journal of Diabetes Research
- Effects of a high-protein/low-carbohydrate versus a standard hypocaloric diet on adipocytokine levels and cardiovascular risk factors during 9 months, role of rs6923761 gene variant of glucagon-like peptide 1 receptor
- (2015) D. A. de Luis et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Relation of the rs6923761 Gene Variant in Glucagon-Like Peptide 1 Receptor to Metabolic Syndrome in Obese Subjects
- (2014) Daniel Antonio de Luis et al. ANNALS OF NUTRITION AND METABOLISM
- Role of the rs6923761 Gene Variant in Glucagon-Like Peptide 1 Receptor Gene on Cardiovascular Risk Factors and Weight Loss after Biliopancreatic Diversion Surgery
- (2014) Daniel Antonio de Luis et al. ANNALS OF NUTRITION AND METABOLISM
- Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients
- (2014) Chun-Jun Li et al. Cardiovascular Diabetology
- GLP-1 Plays a Limited Role in Improved Glycemia Shortly After Roux-en-Y Gastric Bypass: A Comparison With Intensive Lifestyle Modification
- (2014) Marion L. Vetter et al. DIABETES
- Chronic Reduction of GIP Secretion Alleviates Obesity and Insulin Resistance Under High-Fat Diet Conditions
- (2014) D. Nasteska et al. DIABETES
- GLP-1 Agonism Stimulates Brown Adipose Tissue Thermogenesis and Browning Through Hypothalamic AMPK
- (2014) D. Beiroa et al. DIABETES
- Circulating Glucagon-like Peptide-1 (GLP-1) Inhibits Eating in Male Rats by Acting in the Hindbrain and Without Inducing Avoidance
- (2014) Mukesh Punjabi et al. ENDOCRINOLOGY
- GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?
- (2014) S. Brunton INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss
- (2014) Anna Secher et al. JOURNAL OF CLINICAL INVESTIGATION
- Relation of the rs6923761 Gene Variant in Glucagon-Like Peptide 1 Receptor with Weight, Cardiovascular Risk Factor, and Serum Adipokine Levels in Obese Female Subjects
- (2014) Daniel Antonio de Luis et al. JOURNAL OF CLINICAL LABORATORY ANALYSIS
- A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
- (2014) Brian Finan et al. NATURE MEDICINE
- Laparoscopic Sleeve Gastrectomy Versus Single Anastomosis (Mini-) Gastric Bypass for the Treatment of Type 2 Diabetes Mellitus: 5-Year Results of a Randomized Trial and Study of Incretin Effect
- (2014) Wei-Jei Lee et al. OBESITY SURGERY
- Weight loss effect of glucagon-like peptide-1 mimetics on obese/overweight adults without diabetes: A systematic review and meta-analysis of randomized controlled trials胰高血糖素样肽-1类似物对非糖尿病肥胖/超重成人的减重作用：一篇对随机对照试验进行的系统评价及meta分析
- (2014) Fang Zhang et al. Journal of Diabetes
- Cardiovascular risk factors and adipocytokines levels after two hypocaloric diets with different fat distribution in obese subjects and rs6923761 gene variant of glucagon-like peptide 1 receptor
- (2014) Daniel Antonio de Luis et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Effect of rs6923761 gene variant of glucagon-like peptide 1 receptor on metabolic response and weight loss after a 3-month intervention with a hypocaloric diet
- (2014) Daniel Antonio de Luis et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Glucagon-like peptide-1 (GLP-1) and its split products GLP-1(9-37) and GLP-1(28-37) stabilize atherosclerotic lesions in apoe−/− mice
- (2013) Mathias Burgmaier et al. ATHEROSCLEROSIS
- Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
- (2013) Jonathan E. Campbell et al. Cell Metabolism
- Contribution of Endogenous Glucagon-Like Peptide 1 to Glucose Metabolism After Roux-en-Y Gastric Bypass
- (2013) M. Shah et al. DIABETES
- Comparative Effects of Prolonged and Intermittent Stimulation of the Glucagon-Like Peptide 1 Receptor on Gastric Emptying and Glycemia
- (2013) M. M. Umapathysivam et al. DIABETES
- GLP-1 Action and Glucose Tolerance in Subjects With Remission of Type 2 Diabetes After Gastric Bypass Surgery
- (2013) A. Jimenez et al. DIABETES CARE
- Exenatide-Induced Reduction in Energy Intake Is Associated With Increase in Hypothalamic Connectivity
- (2013) H. Schlogl et al. DIABETES CARE
- Secretion of Glucose-Dependent Insulinotropic Polypeptide in Patients With Type 2 Diabetes: Systematic review and meta-analysis of clinical studies
- (2013) S. Calanna et al. DIABETES CARE
- The once-daily human GLP-1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short-term treatment
- (2013) A. Flint et al. DIABETES OBESITY & METABOLISM
- Incretins: Their physiology and application in the treatment of diabetes mellitus
- (2013) Hale M. Tasyurek et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies
- (2013) S. Calanna et al. DIABETOLOGIA
- Functional Analysis of Seven Genes Linked to Body Mass Index and Adiposity by Genome-Wide Association Studies: A Review
- (2013) John R. Speakman HUMAN HEREDITY
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
- (2013) J van Can et al. INTERNATIONAL JOURNAL OF OBESITY
- Genetic association analysis of 30 genes related to obesity in a European American population
- (2013) P Li et al. INTERNATIONAL JOURNAL OF OBESITY
- Obesity: The Gateway to Ill Health - an EASO Position Statement on a Rising Public Health, Clinical and Scientific Challenge in Europe
- (2013) Gema Frühbeck et al. Obesity Facts
- Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity
- (2013) Giuseppina Opinto et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Effects of Roux-en-Y gastric bypass on energy and glucose homeostasis are preserved in two mouse models of functional glucagon-like peptide-1 deficiency
- (2013) Mohamad Mokadem et al. Molecular Metabolism
- Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: the Preventing Overweight Using Novel Dietary Strategies trial
- (2012) Qibin Qi et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Obesity susceptibility loci and dietary intake in the Look AHEAD Trial
- (2012) Jeanne M McCaffery et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Direct Control of Brown Adipose Tissue Thermogenesis by Central Nervous System Glucagon-Like Peptide-1 Receptor Signaling
- (2012) S. H. Lockie et al. DIABETES
- Genetic Variation in the Glucose-Dependent Insulinotropic Polypeptide Receptor Modifies the Association between Carbohydrate and Fat Intake and Risk of Type 2 Diabetes in the Malmö Diet and Cancer Cohort
- (2012) Emily Sonestedt et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Glucagon-Like Peptide 1 (GLP-1) Analogue, Exendin-4, Decreases the Rewarding Value of Food: A New Role for Mesolimbic GLP-1 Receptors
- (2012) S. L. Dickson et al. JOURNAL OF NEUROSCIENCE
- Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes
- (2012) NATURE GENETICS
- The effect of glucagon-like peptide 1 on cardiovascular risk
- (2012) Jacob Sivertsen et al. Nature Reviews Cardiology
- GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease
- (2012) Jinmi Lee et al. Diabetes & Metabolism Journal
- Rapid Tachyphylaxis of the Glucagon-Like Peptide 1-Induced Deceleration of Gastric Emptying in Humans
- (2011) M. A. Nauck et al. DIABETES
- Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity
- (2011) F. K. Knop et al. DIABETES OBESITY & METABOLISM
- Glucagon-like peptide-1 receptor activation stimulates hepatic lipid oxidation and restores hepatic signalling alteration induced by a high-fat diet in nonalcoholic steatohepatitis
- (2011) Gianluca Svegliati-Baroni et al. LIVER INTERNATIONAL
- Comparative Effects of the Long-Acting GLP-1 Receptor Ligands, Liraglutide and Exendin-4, on Food Intake and Body Weight Suppression in Rats
- (2011) Matthew R. Hayes et al. Obesity
- Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential
- (2011) S. S. Torekov et al. Obesity Reviews
- Differential processing of pro-glucose-dependent insulinotropic polypeptide in gut
- (2010) Yukihiro Fujita et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Detailed Physiologic Characterization Reveals Diverse Mechanisms for Novel Genetic Loci Regulating Glucose and Insulin Metabolism in Humans
- (2010) E. Ingelsson et al. DIABETES
- Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
- (2010) M. A. Nauck et al. DIABETOLOGIA
- Molecular mechanisms underlying nutrient-stimulated incretin secretion
- (2010) Helen E. Parker et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway
- (2010) Nitika Arora Gupta et al. HEPATOLOGY
- Effect of Administration Time of Exenatide on Satiety Responses, Blood Glucose, and Adverse Events in Healthy Volunteers
- (2010) Nicole R. Pinelli et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index
- (2010) Elizabeth K Speliotes et al. NATURE GENETICS
- Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge
- (2010) Richa Saxena et al. NATURE GENETICS
- Differential incretin effects of GIP and GLP-1 on gastric emptying, appetite, and insulin-glucose homeostasis
- (2010) T. Edholm et al. NEUROGASTROENTEROLOGY AND MOTILITY
- Variants from GIPR, TCF7L2, DGKB, MADD, CRY2, GLIS3, PROX1, SLC30A8 and IGF1 Are Associated with Glucose Metabolism in the Chinese
- (2010) Cheng Hu et al. PLoS One
- GIP and GLP-1, the two incretin hormones: Similarities and differences
- (2010) Yutaka Seino et al. Journal of Diabetes Investigation
- Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver
- (2009) Giovanni Musso et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- On the role of glucose-dependent insulintropic polypeptide in postprandial metabolism in humans
- (2009) Meena Asmar et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Effects of peripheral administration of synthetic human glucose-dependent insulinotropic peptide (GIP) on energy expenditure and subjective appetite sensations in healthy normal weight subjects and obese patients with type 2 diabetes
- (2009) C. Daousi et al. CLINICAL ENDOCRINOLOGY
- Endogenous Glucagon-Like Peptide-1 Slows Gastric Emptying in Healthy Subjects, Attenuating Postprandial Glycemia
- (2009) Adam M. Deane et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
- (2008) Helle Linnebjerg et al. REGULATORY PEPTIDES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started